REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September...
Covered in this story
What has happened since
- Regeneron Pharmaceuticals is down 0.1% since this was published, 37 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Regeneron Pharmaceuticals
- Jefferies: $735 → $930 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.